ATXI · Avenue Therapeutics, Inc. · Executive Compensation
$0.38
-0.05 (-10.71%)
At close · Mar 19
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors individually and collectively cause substantial doubt about the Company's ability to continue as a going concern to exist within one year from the date of this report.”View the 10-Q filed Aug 7, 2026
Market Cap
$848,783
Shares
3.29M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | Former Chief Executive Officer | $570,859 |
| Alexandra MacLean | Chief Executive Officer | $280,542 |
| Joseph Vazzano | Former Chief Financial Officer | $21,335 |
| David Jin | Interim Chief Financial Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | Former Chief Executive Officer | $1,082,128 |
| Joseph Vazzano | Former Chief Financial Officer | $441,325 |
| David Jin | Interim Chief Financial Officer | — |
| Alexandra MacLean | Chief Executive Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | Chief Executive Officer | $443,027 |
| Joseph Vazzano | Chief Financial Officer | $214,890 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | Chief Executive Officer | $639,783 |
| Joseph Vazzano | Chief Financial Officer | $258,779 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Lucy Lu | Chief Executive Officer | $1,594,633 |
| Joseph Vazzano | Chief Financial Officer | $354,528 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Lindsay A. Rosenwald, M.D. | Director | Appointed | 2024-06-26 |
| Alexandra MacLean, M.D. | Director | Appointed | 2024-06-26 |
| Curtis Oltmans | Director | Appointed | 2024-06-26 |
| Faith Charles | Director | Appointed | 2024-06-26 |
| Neil Herskowitz | Director | Appointed | 2024-06-26 |
| Jay Kranzler, M.D., Ph.D. | Director | Appointed | 2024-06-26 |